These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32473104)

  • 1. Treatment of Localized Cutaneous Leishmaniasis With Intralesional Meglumine Antimoniate and Photodynamic Therapy.
    Costin A; Bonito F; Alves J; Barreiros H
    Actas Dermosifiliogr (Engl Ed); 2020 Dec; 111(10):897-899. PubMed ID: 32473104
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series.
    Arboleda M; Barrantes S; Úsuga LY; Robledo SM
    Rev Soc Bras Med Trop; 2019 May; 52():e20180211. PubMed ID: 31141044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis.
    Duque MC; Vasconcellos ÉC; Pimentel MI; Lyra MR; Pacheco SJ; Marzochi MC; Rosalino CM; Schubach AO
    Rev Soc Bras Med Trop; 2016; 49(6):774-776. PubMed ID: 28001228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis.
    Solomon M; Ollech A; Pavlotsky F; Barzilai A; Schwartz E; Baum S; Astman N
    Acta Derm Venereol; 2024 Apr; 104():adv35089. PubMed ID: 38682801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate.
    Aste N; Pau M; Ferreli C; Biggio P
    Br J Dermatol; 1998 Feb; 138(2):370-1. PubMed ID: 9602904
    [No Abstract]   [Full Text] [Related]  

  • 6. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis.
    Mujtaba G; Khalid M
    Int J Dermatol; 1999 Aug; 38(8):607-9. PubMed ID: 10487452
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
    Faghihi G; Tavakoli-kia R
    Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities.
    Pimentel MIF; Vasconcellos ÉCFE; Ribeiro CO; Lyra MR; Saheki MN; Salgueiro MM; Antonio LF; Schubach AO
    Rev Soc Bras Med Trop; 2017; 50(2):269-272. PubMed ID: 28562769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma antimony determination during cutaneous leishmaniasis treatment with intralesional infiltration of meglumine antimoniate.
    de Aguiar MG; Gonçalves JE; Souza MD; de Silva RE; Silveira JN; Cota G
    Trop Med Int Health; 2018 Oct; 23(10):1110-1117. PubMed ID: 30053341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate.
    Ferreira e Vasconcellos Ede C; Pimentel MI; Valete-Rosalino CM; Madeira Mde F; Schubach Ade O
    Rev Inst Med Trop Sao Paulo; 2014; 56(4):361-2. PubMed ID: 25076440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006).
    Vasconcellos Ede C; Pimentel MI; Schubach Ade O; de Oliveira Rde V; Azeredo-Coutinho RB; Silva Fda C; Salgueiro Mde M; Moreira JS; Madeira Mde F; Baptista C; Valete-Rosalino CM
    Am J Trop Med Hyg; 2012 Aug; 87(2):257-60. PubMed ID: 22855754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antimonial treatments of leishmaniasis].
    Oliveira Neto MP
    Rev Soc Bras Med Trop; 2005; 38(5):446. PubMed ID: 16172767
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device.
    Bogenrieder T; Lehn N; Landthaler M; Stolz W
    Dermatology; 2003; 206(3):269-72. PubMed ID: 12673089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis.
    Asilian A; Sadeghinia A; Faghihi G; Momeni A; Amini Harandi A
    Ann Trop Med Parasitol; 2003 Jul; 97(5):493-8. PubMed ID: 12930612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit.
    de Oliveira Duque MC; Quintão Silva JJ; Soares PAO; Magalhães RS; Horta APA; Paes LRB; Rosandiski Lyra M; Pimentel MIF; de Fátima Antonio L; de Camargo Ferreira E Vasconcellos É; Saheki MN; de Almeida Marzochi MC; Valete-Rosalino CM; de Oliveira Schubach A
    Acta Trop; 2019 May; 193():176-182. PubMed ID: 30851256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis.
    Brito NC; Machado de Assis TS; Rabello A; Cota G
    PLoS Negl Trop Dis; 2019 Dec; 13(12):e0007856. PubMed ID: 31805052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety profile of meglumine antimoniate intralesional infiltration for cutaneous leishmaniasis.
    Fernandes HJ; da Silva RE; Ramalho DB; Aguiar MG; Silveira JN; Cota G
    Expert Rev Anti Infect Ther; 2020 Apr; 18(4):381-387. PubMed ID: 32067521
    [No Abstract]   [Full Text] [Related]  

  • 18. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
    Moosavian SA; Fallah M; Jaafari MR
    Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran.
    Zerehsaz F; Salmanpour R; Handjani F; Ardehali S; Panjehshahin MR; Tabei SZ; Tabatabaee HR
    Int J Dermatol; 1999 Aug; 38(8):610-2. PubMed ID: 10487453
    [No Abstract]   [Full Text] [Related]  

  • 20. Localized leishmaniasis treated with intralesional meglumine antimoniate.
    Villela-Segura U; Proy-Trujillo H; Ilizaliturri-Flores I; Leal-Ascencio VJ; Eljure-López N
    J Dtsch Dermatol Ges; 2020 Sep; 18(9):1025-1027. PubMed ID: 32656933
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.